Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk (Q35181647)

7 August 2017

1 reference

title

Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk (English)

1 reference

7 August 2017

0 references

1 reference

1 reference

1 reference

Marie-Christine Alessi

1 reference

ORCID Public Data File 2021

author name string

Juhan-Vague I

1

1 reference

7 August 2017

Alessi MC

2

1 reference

7 August 2017

Mavri A

3

1 reference

7 August 2017

Morange PE

4

1 reference

7 August 2017

1 July 2003

1 reference

Journal of Thrombosis and Haemostasis

7 August 2017

1 reference

7 August 2017

1

1 reference

7 August 2017

1575-1579

1 reference

7 August 2017

7

1 reference

Plasminogen-activator inhibitor type 1 and coronary artery disease

7 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Adipose tissue as a buffer for daily lipid flux

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Inflammatory status and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Inflammation in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Orexin-A augments voltage-gated Ca2+ currents and synergistically increases growth hormone (GH) secretion with GH-releasing hormone in primary cultured ovine somatotropes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Induction of plasminogen activator inhibitor type-1 (PAI-1) by proinsulin and insulin in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

A Forkhead/winged helix-related transcription factor mediates insulin-increased plasminogen activator inhibitor-1 gene transcription.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Angiotensin and vascular fibrinolytic balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Tumor necrosis factor alpha is a key component in the obesity-linked elevation of plasminogen activator inhibitor 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Subcutaneous abdominal, but not femoral fat expression of plasminogen activator inhibitor-1 (PAI-1) is related to plasma PAI-1 levels and insulin resistance and decreases after weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat: evidence of differences between visceral and subcutaneous deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Proinsulin and insulin concentrations in relation to carotid wall thickness: Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Endogenous vitronectin and plasminogen activator inhibitor-1 promote neointima formation in murine carotid arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Influence of PAI-1 on adipose tissue growth and metabolic parameters in a murine model of diet-induced obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1538-7836.2003.00279.X

10.1046/J.1538-7836.2003.00279.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference